Figure 0个  Table 1个
    • Developer Product description Stage
      Takeda Pharmaceuticals/Inviragen Live attenuated DNA tetravalent vaccine (attenuated DEN2 PDK-53 virus and DEN/DEN intertypic chimeric viruses) Phase 2
      National Institutes of Allergy and Infectious Diseases/Butantan Institute Live attenuated vaccine (targeted mutagenesis of DEN viruses and DEN/DEN intertypic chimeric virus) Phase 2
      Sanofi Pasteur ChimericVax-Dengue. Live attenuated tetravalent vaccine (Yellow Fever 17D/DEN chimeric viruses) Phase 3
      The Walter Reed Army Institute of Research and GlaxoSmithKline Biologicals Live attenuated DNA tetravalent vaccine attenuated in PDK-53 cells and fetal rhesus lung (FRhL) cells) Phase 2
      Center for Genetic Engineering and Biotechnology Recombinant protein PD5 (domain Ⅲ of the envelope E protein from DENV-2 fused to the protein carrier p64k)/Recombinant domain Ⅲ-capsid protein (comprises the domain Ⅲ region of the envelope protein and the capsid protein, both from DENV-2) Preclinical trials
      Merck/Hawaii Biotech Recombinant DEN1-80E subunit protein vaccine (truncated E version) Phase 1
      GlaxoSmithKline/Oswaldo Cruz Foundation/Walter Reed Army Institute of Research DEN1, purified inactivated virus vaccine Phase 1
      Naval Medical Research Center, Viral & Rickettsial Diseases Department Developed by incorporating pre-membrane and envelope genes into a plasmid vector and expresses the prM and E genes of DENV-1 Phase 1
      The Naval Medical Research Center and Walter Reed Army Institute of Research Priming with tetravalent purified inactivated virus (TPIV) expressing the structural prM/E gene region (TDNA) then boosting with a tetravalent live attenuated virus (TLAV) vaccine Preclinical trials
      Department of Microbiology, School of Basic Medical Sciences, Capital Medical University Developed recombinant plasmid (pCAGGSP7 and internal ribosome entry site (IRES)) expressing DENV antigens of prM-E or prM-E-NS1 of DENV Preclinical trials
      International Centre for Genetic Engineering and Biotechnology, New Delhi, India Based on DENV-2 E protein VLPs developing virus-vectored DENV vaccine Preclinical trials
      *Adapted from references (Arora U, et al., 2013; Beckett C G, et al., 2011; Lu H, et al., 2013; Simmons M, et al., 2010; Sinha G, 2014; Thomas S J, et al., 2013; Valdés I, et al., 2010; Valdes I, et al., 2011)

      Table 1.  Dengue vaccines in clinical development*